Attached files
file | filename |
---|---|
EX-99 - PRESS RELEASE - Cellular Biomedicine Group, Inc. | cbmg_ex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 20, 2016 (April 15, 2016)
CELLULAR BIOMEDICINE GROUP, INC.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-36498 |
|
86-1032927 |
(State or other Jurisdiction of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
19925 Stevens Creek Blvd., Suite 100
Cupertino, California |
|
95014 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (408) 973-7884
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 3.02 Unregistered Sales of Equity Securities.
On April 15, 2016, Cellular Biomedicine Group, Inc. (the “Company”) completed the second and final closing of a transaction (the “Financing”) with Wuhan Dangdai Science & Technology Industries Group Inc. (the “Investor”), pursuant to which the Company sold to the Investor 2,006,842 shares of the Company’s common stock, par value
$0.001 per share (the “Common Stock”), for approximately $38,130,000 in gross proceeds. As previously disclosed in a Current Report on Form 8-K filed on February 10, 2016, the Company conducted the initial closing of the Financing on February 4, 2016. The aggregate gross proceeds from both closings in the Financing totaled approximately $43,130,000. In the aggregate, 2,270,000 shares of Common Stock were issued in the Financing (the “Shares”).
In connection with the Financing, the Company has agreed to file a registration statement covering the resale of the Shares within 90 days of closing. The Company also granted to the Investor certain “piggy-back” registration rights, which are triggered at any time when there is not an effective registration statement covering all of the registrable securities
and the Company determines to prepare and file a registration statement under the Securities Act of 1933, as amended (the “Securities Act”), relating to an offering of the Company’s securities for the Company’s account or the account of a merger target (subject to certain exceptions, including but not limited to a registration statement on Form S-4 or Form S-8).
The issuance of the Shares was made in reliance on the exemption from registration provided by Regulation S under the Securities Act.
In connection with the Financing, the Company will pay a finder’s fee equal to 5% of the gross proceeds, which fee is payable either in cash from the gross proceeds of the Financing, in restricted shares of Common Stock, or a combination of both. Any portion of the fee paid in shares will be based on the per share purchase price in the Financing of $19 per share. The
issuance of any such shares to the finder will be made in reliance on the exemption from registration provided by Regulation S under the Securities Act.
Item 8.01. Other Events.
On April 19, 2016, the Company issued a press release announcing the final closing of the Financing, a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No |
Description |
99.1 |
Press Release, dated April 19, 2016 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Cellular Biomedicine Group, Inc. |
| |
|
|
|
|
Date: April 20, 2016 |
By: |
/s/ Bizuo (Tony) Liu |
|
|
|
Bizuo (Tony) Liu
Chief Executive Officer |
|
|
|
|
|